Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
Johnson & Johnson completed the acquisition of Firefly Bio for $1 billion in cash, adding the proprietary Firelink degrader antibody conjugate platform to its oncology portfolio. The technology is designed to deliver protein degraders directly to cancer cells, targeting KRAS-driven and other difficult-to-treat solid tumors.
Key figures
- Deal Value Usd
- 1000000000
- Iprd charge
- 1000000000
- Eps dilution 2026
- 0.46
- Eps dilution 2027
- 0.08
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.